Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does levodopa aggravate Parkinson's disease?

J Blin1, A M Bonnet, Y Agid

  • 1Laboratoire de Médecine Expérimentale, INSERM U 289, Hôpital de la Salpêtrière, Paris, France.

Neurology
|September 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnostic value of visual evoked potential in toxic and nutritional optic neuropathies].

Journal francais d'ophtalmologie·2026
Same author

[Retinal arteriovenous malformation in Wyburn-Mason syndrome].

Journal francais d'ophtalmologie·2024
Same author

Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms.

Scientific reports·2021
Same author

Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction?

European journal of neurology·2013
Same author

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Breast cancer research and treatment·2013
Same author

Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.

Neurology·2006
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Levodopa therapy does not worsen Parkinson's disease progression. Early initiation of levodopa treatment, even in patients with involuntary movements, is linked to motor symptom severity, not earlier onset of side effects.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder.
  • Levodopa is a primary treatment for Parkinson's disease.
  • Concerns exist regarding potential long-term adverse effects of levodopa therapy.

Purpose of the Study:

  • To investigate the potential deleterious effects of levodopa therapy on Parkinson's disease progression.
  • To determine if early initiation of levodopa therapy influences the onset of levodopa-induced abnormal involuntary movements.

Main Methods:

  • Retrospective analysis of 185 Parkinson's disease patients regarding levodopa treatment parameters (timing, dose, duration).
  • Analysis of 72 parkinsonian patients with levodopa-induced abnormal involuntary movements to assess the impact of early levodopa initiation.

Related Experiment Videos

Main Results:

  • Levodopa introduction timing, daily dose, and treatment duration did not aggravate Parkinson's disease.
  • Early levodopa initiation did not affect the onset time of abnormal involuntary movements in patients experiencing them.
  • Patients with early levodopa initiation had more severe motor disability.

Conclusions:

  • Levodopa therapy, within the studied parameters, does not appear to worsen the underlying progression of Parkinson's disease.
  • Early levodopa treatment is likely initiated due to disease severity rather than influencing the timing of side effect onset.